Drug reimportation decreases power of FDA's standards

09/6/2013 | Life Science Leader

Laws that validate drug reimportation empower counterfeit drug activity and motivate lawful foreign-based drugmakers not to comply with FDA standards, Rob Wright writes. Many drugs that U.S. consumers want to reimport are cheaper because they are produced under lesser standards of quality, Wright writes.

View Full Article in:

Life Science Leader